Did a switch to a generic antidepressant cause relapse?

Journal of Family Practice

Volumn 57, Issue 2, 2008, Pages 109-114

  Rosenthal, Jessica ^a,b,c   Kong, Brian ^a,b,d   Jacobs, Leslie ^a   Katzman, Martin A ^a,e,f,g,h,i  

^a START Clinic for Mood and Anxiety Disorders

^b THE CHICAGO SCHOOL OF PROFESSIONAL PSYCHOLOGY   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f Northern School of Medicine

^g LAURENTIAN UNIVERSITY   (Canada)

^h LAKEHEAD UNIVERSITY   (Canada)

ⁱ START Clinic for Mood and Anxiety Disorders   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CITALOPRAM; ESCITALOPRAM; GENERIC DRUG; MOOD STABILIZER; NEUROLEPTIC AGENT; PAROXETINE; QUETIAPINE; TOPIRAMATE; TRAZODONE;

ADULT; ANXIETY DISORDER; BIOEQUIVALENCE; CLINICAL ARTICLE; COGNITIVE THERAPY; DEPRESSION; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE; HUMAN; PHARMACY BENEFIT MANAGER; PRACTICE GUIDELINE; RELAPSE; REVIEW; RISK ASSESSMENT;

ADULT; ANTIDEPRESSIVE AGENTS; COST SAVINGS; DEPRESSIVE DISORDER; DRUGS, GENERIC; FAMILY PRACTICE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 39449132128     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (9)

1. US Food and Drug Administration. FDA announces initiative to bolster generic drug program. Available at: www.fda.gov/bbs/topics/NEWS/2007/NEW01719. html. Accessed January 8, 2007.
2. Stagnitti MN. AHRQ Statistical Brief #163: Trends in the Use and Expenditures for the Therapeutic Class Prescribed Psychotherapeutic Agents and All Subclasses, 1997 and 2004. Available at: www.meps.ahrq.gov/mepsweb/ data_files/publications/st163/stat163.pdf. Accessed January 8, 2007.
3. Van Ameringen M, Mancini C, Patterson B, Bennett M. Symptom relapse following switch from Celexa to generic citalopram: an anxiety disorders case series. J Psychopharm 2007; 21:472-476.
4. Stenson J. Report Questions Generic Antidepressant. msnbc.com. October 12 & 15, 2007. Available at: www.nbc6.net/msnbchealth/14327700/detail.html. Accessed January 8, 2008.
5. Borgherini G. The bioequivalence and therapeutic efficacy of generic versus brand name psychoactive drugs. Clin Ther 2003; 25:1578-1592.
6. Meyer MC. United States Food and Drug Administration requirements for approval of generic drug product. J Clin Psychiatry 2001; 62(suppl 5):4-9.
7. Vergouwen AC, Bakker A. Adverse effects after switching to a different generic form of paroxetine: Paroxetine mesylate instead of paroxetine KCl hemihydrate [in Dutch]. Ned Tijdschr Geneeskd 2002; 146:811-812.
8. Cassano P, Fava M. Tolerability issues during long term treatment with antidepressants. Ann Clin Psychiatry 2005; 16:15-25.
9. Cantor LB. Generic: Not all drugs are created equal. Rev Ophthalmol [serial online] 2002; 9:72-74.